The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. Year to date metric has recorded a gain of 9.86%.However, over the last six months, we can see a weaker performance of 13.45%. Over the last 30 days, the price of HUMA has leaped by -10.34%. And in the last five days, it has surged by 0.65%.
Humacyte Inc saw a rather consistency, in terms of market performance. The company’s stock reached its highest point at $5.60 on 05/08/23, while the lowest price for the same duration was marked at $1.96 on 11/01/23.
52-week price history of HUMA Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Humacyte Inc’s current trading price is -44.29% away from its 52-week high, while its distance from the 52-week low is 59.18%. The stock’s price range during this period has varied between$1.96 and $5.60. The Humacyte Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.3 million for the day, a figure considerably higher than their average daily volume of 0.96 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Humacyte Inc (HUMA) has experienced a quarterly rise of 16.85% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 371.53M and boasts a workforce of 183 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.11, with a change in price of +0.93. Similarly, Humacyte Inc recorded 769,826 in trading volume during the last 100 days, posting a change of +42.47%.
HUMA’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for HUMA stands at 4.29. Similarly, the long-term debt-to-equity ratio is also 4.10.
HUMA Stock Stochastic Average
As of today, Humacyte Inc’s raw stochastic average for the last 50 days stands at 15.55%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 29.87%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 19.09% and 12.63%, respectively.
